Table 6 Summary of disease definition across trials
From: Systematic review of outcome measures in pediatric eosinophilic esophagitis treatment trials
|  | Konikoff [18] | Schaefer [19] | Assa’ad [21] | Dohil [20] | Spergel [22] | Gupta [23] | Teva Pharm [27] NCT00635089 | Page [25] NCT01458418 | Di Nardo [26] NCT01846962 | McGuire Davis [28] NCT01821898 | Heine [24] ACTRN12613001210763 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Initiated after 2007? | No | No | No | Yes (2008) | Yes (2008) | Yes (2008) | Yes (2008) | Yes (2011) | Yes (2013) | Yes (2013) | Yes (2013) |
Met FIGER criteria? | N/A | N/A | N/A | Yes | Yesa | No | Yesb | No | Yes | No | No |
Reason for not meeting criteria | No acid suppression or symptoms required | Â | No symptoms required | Â | Â | No pH test or PPI trial required | Â | No symptoms required | Â | No symptoms required | No pH test or PPI trial required |
Initiated after 2011? | No | No | No | No | No | No | No | Yes | Yes | Yes | Yes |
Meet updated consensus criteria? | N/A | N/A | N/A | N/A | N/A | N/A | N/A | No symptoms indicated, no requirement for failed PPI trial | yes | No requirement for failed PPI trial for 8Â weeks, requirement for >20 Eo/HPF | No requirement for failed PPI trial for 8Â weeks, requirement for >20 Eo/HPF |